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Background: Prevalence of ﬂuoroquinolone (FQ)-resistant Escherichia coli has been recently increasing
worldwide. We analyzed the incidence and characteristics of acute bacterial prostatitis after transrectal
ultrasound-guided needle prostate biopsy (TRUSP-Bx) with prophylactic tazobactam/piperacillin (TAZ/
PIPC) treatment as an alternative regimen.
Methods: A total of 391 patients who underwent TRUSP-Bx were included in the study. All patients
received intravenous TAZ/PIPC (4.5 g) 30 minutes before and 6 hours after TRUSP-Bx.
Results: Acute bacterial prostatitis developed in six patients (1.5%); the frequency of its occurrence was
signiﬁcantly higher in patients in whom rectal disinfection was not performed (P< 0.05). These six pa-
tients developed clinical symptoms of acute bacterial prostatitis a median of 24 hours after the biopsy.
Escherichia coliwas isolated in urine or blood bacterial cultures in four cases, and Klebsiella pneumoniae in
two cases. All of the isolated organisms showed excellent sensitivity to TAZ/PIPC.
Conclusions: The incidence rate of acute prostatitis with prophylactic TAZ/PIPC was consistent with
those reported previously with FQ-based regimens, despite the favorable sensitivity of isolated organ-
isms. Two-time regimen of TAZ/PIPC may not always prevent the post-TRUSP-Bx infection, possibly due
to the pharmacokinetic characteristics of TAZ/PIPC. However, if each case was considered individually to
select the best setting and frequency of dosage of TAZ/PIPC, this can be an optimal prophylaxis in the era
of widespread FQ-resistant microorganisms.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Transrectal ultrasound-guided needle prostate biopsy (TRUSP-
Bx) is generally accepted as a standard procedure for the diagnosis
of prostate cancer. Bacterial infection is one of the most serious
complications associated with TRUSP-Bx. The incidence of bacterial
complications, such as acute prostatitis, ranges from 1% to 5% [1e3].
Therefore, pre-procedure antibiotic prophylaxis is usually per-
formed to reduce the risk of bacterial infection. Because ﬂuo-
roquinolones (FQs) have a broad spectrum of activity against aIshikawa Prefectural Central
20-8530, Japan.
igehara).
ciﬁc Prostate Society, Published bmajority of Gram-negative bacteria and exhibit excellent prostatic
tissue bioavailability [4e6], they are widely used as antibiotic
prophylaxis with TRUSP-Bx.
However, prevalence of FQ-resistant Escherichia coli has been
recently increasing worldwide [7e10], and a trend of increasing
resistance to FQs has also been observed in Japan [7,8]. Actually,
some previous reports have demonstrated emergence of FQ-
resistant E. coli infections following TRUSP-Bx after prophylactic
use of FQs [11,12]. Therefore, other prophylactic antibiotic regi-
mens need to be considered to decrease the risk of infectious
complications of TRUSP-Bx in the era of widespread FQ-resistant
microorganisms.
In the present study, we evaluated the prophylactic efﬁcacy of
intravenous tazobactam/piperacillin (TAZ/PIPC) for use with
TRUSP-Bx. We analyzed the incidence rate, clinical characteristics,y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 103e106104and bacterial cultures of acute bacterial prostatitis occurring after
TRUSP-Bx with prophylactic TAZ/PIPC administration.
Materials and methods
A total of 391 patients who underwent TRUSP-Bx at Ishikawa
Prefectural Central Hospital, Kanazawa, Japan between January
2010 and August 2012 were included in our study. The indications
for TRUSP-Bx were as follows: elevation of serum prostate-speciﬁc
antigen levels or aberrant ﬁndings on digital rectal examination
(DRE) based on the criteria of a mass prostate-speciﬁc antigen ex-
amination in Kanazawa City as described previously [13]. Before the
prostate biopsy, all patients underwent urinalysis, DRE, and trans-
rectal ultrasound to conﬁrm the absence of signs of urinary tract
infections. All biopsies were TRUSP-Bx, and an automatic biopsy
gun with an 18-gauge needle was used to obtain 8-core biopsies.
None of the patients received an enema before the biopsy. Disin-
fection of the rectum by using an iodine swab was at the discretion
of the attending physician. All patients were administered intra-
venous TAZ/PIPC (4.5 g) twice: 30 minutes before the biopsy and 6
hours after it. All patients were hospitalized at our institution for
one night to observe any possible complications, such as hematuria,
fever, urinary retention, and anal bleeding. Patients without signs
of these complications were discharged the following morning.
Acute bacterial prostatitis caused by TRUSP-Bx was diagnosed
using these criteria: core body temperature > 38C, the presence of
leukocytes in the urine sediment, the isolation of any microor-
ganisms from urine or bladder cultures, and tenderness of the
prostate found on DRE within 7 days of the biopsy. Before the
initiation of antibiotic treatment, all microorganisms isolated from
urine or blood cultures were tested for antibiotic susceptibility. The
minimum inhibitory concentration (MIC) was measured using the
broth microdilution method, based on the criteria of the Clinical
and Laboratory Standards Institute (CLSI). Drug susceptibility was
determined based on the breakpoint MIC established by the CLSI.
We recorded the clinical characteristics and results of bacterial
cultures in patients diagnosed with acute bacterial prostatitis. In
addition, all patients were divided into two groups as follows: pa-
tients with acute bacterial prostatitis after TRUSP-Bx (Group 1) and
patients without bacterial complications after TRUSP-Bx (Group 2).Table 1
Patients' characteristics and comparisons between Group 1 and Group 2.
Categories Group 1 (n¼ 6)
Acute prostatitis
Median age (range) 66 (54e74)
Median prostate volume (mL) 21.4
Rate of diabetes mellitus (%) 0 (0.0)
Median IPSS score 11.5
Rate of rectum sterilization (%) 2 (33.3)
No. of re-biopsy 2 (33.3)
IPSS, international prostatic symptoms score.
Table 2
Details of patients with acute bacterial prostatitis after transrectal prostate needle biops
No. Age (yr) Biopsy numbers Interval a)
(hr) Antib
1 60 1 6 ME
2 68 2 24 SBT
3 74 1 168 CAZ
4 64 1 6 CTM
5 68 1 24 LVF
6 54 2 72 CTR
a) Interval from biopsy to appearance of acute bacterial prostatitis.
CAZ, ceftazidime; CTM, cefotiam; CTRX, ceftriaxone; LVFX, levoﬂoxacin; MEPM, meropeWe then analyzed the risk factors for acute bacterial prostatitis after
TRUSP-Bx.
The Chi-square test was used to compare patients’ background
characteristics between the two groups. The Mann-Whitney U test
was used for comparison of the age distribution between the two
groups. In all analyses, which were performed using the SPSS
software, version 17.0 (SPSS Inc., Chicago, IL, USA), P< 0.05 was
considered statistically signiﬁcant.
Results
A total of 391 patients, 333 undergoing a ﬁrst biopsy and 58
undergoing a second biopsy, were enrolled in this study. None of
the patients had any deﬁnite clinical signs of a urinary tract infec-
tion before the biopsy based on urinary analysis. The patients’
background characteristics in Group 1 and Group 2 are shown in
Table 1. Acute bacterial prostatitis after TRUSP-Bx occurred in six
patients (1.5%). There was no signiﬁcant difference between Group
1 and Group 2 in patients’ background characteristics regarding
median age, median prostate volume, prevalence of diabetes mel-
litus, and the median International Prostate Symptom Score, and
past histories of TRUSP-Bx. Enforcement of rectal disinfection was
signiﬁcantly lower in Group 1 than in Group 2 (P< 0.05).
Table 2 summarizes the data from the six patients who devel-
oped acute bacterial prostatitis after TRUSP-Bx. The median age of
the patients was 66 years (range, 54e74 years). These patients
developed clinical symptoms of acute bacterial prostatitis a median
of 24 hours after the biopsy (range, 6e168 hours). E. coli was iso-
lated in four cases, and Klebsiella pneumoniae in two cases from
their bacterial cultures. For the treatment of the infections, ceph-
alosporins were used in four patients, carbapenems in one patient,
and FQs in one patient. All patients received immediate antibiotic
administration, and the median duration of treatment was 7 days.
All patients were successfully treated without incidence of septic
shock or death.
Drug susceptibility of the bacterial isolates to a wide range of
antibiotics was also evaluated (Table 3). One isolate was of an
extended-spectrum b-lactamase producing bacteria. All bacteria
isolated from blood and/or urine of the patients with acute bacte-
rial prostatitis showed excellent sensitivity toTAZ/PIPC. In addition,Group 2 (n¼ 385) P
No bacterial complications
68 (51e88) 0.2
27.9 0.33
70 (18.2) 0.25
13.0 0.33
312 (81) 0.0035
55 (14.3) 0.19
y.
Therapy Culture Isolated organisms
iotics (g/d) d Urine Blood
PM 1.5 g 7  þ Escherichia coli
/CPZ 2 g 9 þ  E. coli
2 g 9 þ þ E. coli
3 g 6  þ Klebsiella pneumoniae
X 500 mg 7  þ E. coli
X 2 g 5  þ K. pneumoniae
nem; SBT/CPZ, sulbactam/cefoperazone.
Table 3
Microbiological ﬁndings of the patients with acute bacterial prostatitis.
Patient Bacteria Drug susceptibility
ABPC PIPC CEZ CTM CAZ CPR GM AMK MINO LVFX IPM TAZ/PIPC
1 Escherichia coli S S S S S S S S S S S S
2 E. coli S S S S S S S S S S S S
3 E. coli S S S S S S S S S S S S
4 Klebsiella pneumoniae R R R S R S S S R S S S
5 E. coli R R S S S S S S R S S S
6 K. pneumoniae R S S S S S S S S S S S
ABPC, ampicillin; AMK, amikacin; CAZ, ceftazidime; CEZ, cefazolin; CPR, cefpirome; CTM, cefotiam; GM, gentamycin; IPM, imipenem; LVFX, levoﬂoxacin; MINO, minocycline;
PIPC, piperacillin; R, resistant; S, sensitive; TAZ, tazobactam.
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generation cephalosporins, carbapenems, aminoglycosides, and
FQs, was also excellent.
Discussion
It is widely accepted that prophylactic antibiotics before TRUSP-
Bx are effective in preventing infectious complications. Despite the
use of prophylactic antibiotics, bacterial infections causing fever
occur in 1e5% of patients [6,14e16]. Themost severe complications,
such as urosepsis or septic shock, occur in 0e0.6% of patients
[11,12,15]. Thus, many researchers have attempted to identify the
optimal antibiotic regimen for use with TRUSP-Bx to decrease the
risk of bacterial complications.
In particular, FQs have a broad spectrum of action, which is
adequate for common urinary and colorectal ﬂora. The bioavail-
ability of FQs in the prostatic tissue is known to be high. Therefore,
FQs are the most common prophylactic antibiotics for use with
TRUSP-Bx and are recommended by the American Urological As-
sociation, European Association of Urology, and Japanese Urological
Association (JUA) [17e19]. Indeed, numerous studies have
demonstrated a decrease in the incidence of infectious complica-
tions to rates < 1e4% with FQs use [6,14,16].
By contrast, some recent reports have reported an increase in
the incidence of urinary tract infections after TRUSP-Bx caused by
FQ-resistant microorganisms. Alex et al [10] reported that the
incidence of urinary tract infections after TRUSP-Bx with prophy-
lactic ciproﬂoxacin treatment increased from 0.52% during the
2002e2009 period to 2.15% in 2010e2011; they demonstrated that
the emerging resistance to FQs is the most likely cause for the
increasing risk of infectious complications after TRUSP-Bx. Steen-
sels et al [20] found that seven (3.0%) of 236 patients had infectious
complications after TRUSP-Bx with prophylactic treatment with
ciproﬂoxacin or levoﬂoxacin for 3 days; FQ-resistant E. coli was
isolated in all of their blood cultures. In addition, our previous
report showed that acute prostatitis caused by FQ-resistant E. coli
developed in 1.3% of the patients who received prophylactic oral
levoﬂoxacin (400 mg) combined with intravenous isepamicin sul-
fate (200 mg) [21].
Like FQs, TAZ/PIPC has a wide spectrum of action against
common urinary and colorectal ﬂora, and some reports have
demonstrated the prophylactic efﬁcacy of TAZ/PIPC for bacterial
infections after TRUSP-Bx [22e24]. TAZ/PIPC is a time-dependent
antibiotic agent which differs from FQs in that it has a
concentration-dependent antibiotic action. Surveillance as
described previously in Japan showed that MIC90 values for TAZ/
PIPC against E. coli were 8 mg/mL [24]. A static effect of TAZ/PIPC
can be achieved when the time above the MIC reached 30% of the
dosing interval [25,26]. The MIC of TAZ/PIPC at a dose of 4.5 g
twice/d exceeds 30% of the time above the MIC and was 16 mg/mL
[27], and TAZ/PIPC dosing of 4.5 g twice/d is likely to achieve the
target of MIC90 of TAZ/PIPC against E. coli (30% of the time abovethe MIC) [24,27]. Therefore, we administered TAZ/PIPC twice in
our prophylactic regimen, which consisted of 4.5-g doses given
intravenously 30 minutes before and 6 hours after TRUSP-Bx.
There has been limited information regarding an efﬁcacy of pro-
phylactic TAZ/PIPC for prostate biopsy.
We found that acute prostatitis occurred in six patients (1.5%),
which seems to be consistent with the complication rates reported
previously with other prophylactic regimens. This ﬁnding suggests
that our prophylactic regimen is not inferior to the existing mo-
dalities. However, all microorganisms isolated from bacterial cul-
tures of the patients with acute prostatitis showed excellent
sensitivity to TAZ/PIPC. Therefore, prophylactic two-time intrave-
nous administration of 4.5 g of TAZ/PIPC may not offer the most
optimum pharmacokinetic beneﬁt to all patients who undergo
TRUSP-Bx. In particular, it might not have been the best alternative
for six patients with bacterial acute prostatitis. For this reason, TAZ/
PIPC has a time-dependent antibiotic effect. A maximum bacterial
effect, which is not a static effect of TAX/PIPC, is achieved when the
time above the MIC reaches 50% of the dosing interval [25,26]. The
MIC of TAZ/PIPC at a dose of 4.5 g twice/d exceeds 50% of the time
above theMIC andwas 4 mg/mL [24,27]. By contrast, theMIC of TAZ/
PIPC at a dose of 4.5 g thrice/d exceeds 50% of the time above the
MIC and was 16 mg/mL [24,27]. Therefore, for achievement of a
maximum bacterial effect of TAZ/PIPC, two administrations/
d cannot achieve the target of MIC90 of TAZ/PIPC against E. coli, and
three administrations/d needs to achieve the target of MIC90 of
TAZ/PIPC against E. coli (50% of time above MIC) [24,27]. The re-
ported incidence of asymptomatic transient bacteremia after
TRUSP-Bx ranges from 16% to 73%, and asymptomatic bacteremia
occurs frequently, especially in the patients with various risk fac-
tors such as an enlarged prostate or voiding dysfunction [2].
Therefore, when intravenous TAZ/PIPC is used prophylactically
with TRUSP-Bx, an increased frequency of dosage should be
considered for patients with such risk factors. Indeed, Cormio et al
[23] reported that none of the patients who received a prophylactic
dose of intramuscular TAZ/PIPC (2,250 mg) twice/d for 2 days
developed acute prostatitis. By contrast, Yasuda et al [24] described
that an infectious complication after prostate biopsy was detected
in 2.5% (4/160 patients) in the patients group who received a single
dose of 4.5 g TAZ/PIPC, 30 minutes before the biopsy, and in 0.45%
(2/442 patients) in the group who were administered TAZ/PIPC
twice: 30 minutes before and 5 hours after the biopsy. It was
concluded twice administrations of TAZ/PIPC appear to be effective
as preoperative prophylaxis against the occurrence of febrile in-
fectious complication after TRUSP-Bx. In addition, all of the patients
with acute prostatitis had some risk factors, such as voiding
disturbance, diabetes mellitus, and steroid dosing in this previous
report [24]. The difference in incidence of acute bacterial prostatitis
is likely to be due to the difference in the ratio of the patients with
these risk factors. Therefore, further studies including the setting of
dose intensity of TAZ/PIPC according to risk factors can contribute
to being a better optional prophylaxis for TRUSP-Bx.
Prostate Int 3 (2015) 103e106106Hence, we tried to identify the risk factors for acute prostatitis
after TRUSP-Bx to improve the development of a prophylactic TAZ/
PIPC regimen. Rectal disinfection was found to be the only signiﬁ-
cant factor inﬂuencing the risk of bacterial complications after
TRUSP-Bx. Panupong et al [28] reported that rectal disinfection
before a biopsy signiﬁcantly reduces the incidence of postoperative
bacteremia. In in vitro experiments, Park et al [29] counted bacterial
colonies that were derived from a rectal swab taken before using
povidone-iodine and after the biopsy. They found that the mean
number of colony-forming units decreased by 99.9% after rectal
povidone-iodine preparation. Pu et al reported in their systematic
review and meta-analysis that rectal disinfection with povidone-
iodine signiﬁcantly reduces the incidence of fever, bacteriuria,
and bacteremia [30]. Our ﬁnding also supports a recommendation
of rectal disinfection for patients undergoing TRUSP-Bx. However,
further studies, including various human populations and addi-
tional rectal bacterial evaluations, are required to reach a more
deﬁnitive conclusion. By contrast, we could not identify other risk
factors, such as voiding disturbance and diabetes mellitus, as re-
ported previously for the development of acute bacterial prostatitis
[2,24]. In the present study, a very small number (n¼ 6) of the
patients were included in Group 1, and further studies including a
large number of patients are likely to be required to perform amore
precise analysis.
Although the incidence of sepsis after TRUSP-Bx is relatively
low, some cases of fatal sepsis with delayed antibiotic treatment
have been reported [11,12]. Presently, physicians cannot entirely
prevent bacterial complications after TRUSP-Bx, but prophylactic
measures can be taken. Therefore, sufﬁcient information regarding
the possibility of bacterial complications should be given to the
patients who undergo TRUSP-Bx. In the present study, all patients
with acute prostatitis were treated immediately with antibiotics,
and all were successfully treated without any signs of bacterial
sepsis. However, the species and strains of the isolated bacteria
were somewhat different from the microorganisms isolated from
patients who undergo prophylactic treatment with FQs. In the
present study, E. coliwas isolated in four cases and K. pneumonia in
two cases, whereas FQ-resistant E. coli was detected in most pa-
tients with acute prostatitis after TRUSP-Bx in some previous
studies [10,20,21]. This discrepancy may be due to differences be-
tween TAZ/PIPC and FQs in pharmacokinetics or antibiotic activity
in the prostate. Our bacterial ﬁndings suggest that FQs may now be
the most recommended class of antibiotics for prophylaxis of in-
fections after TRUSP-Bx, and that two-time prophylactic intrave-
nous administration of TAZ/PIPC could not be always effective for
all patients who undergo TRUSP-Bx. However, further studies
including the better setting of dose intensity of TAZ/PIPC can
contribute to being an optional prophylaxis for TRUSP-Bx in the era
of widespread FQ-resistant microorganisms.Conﬂicts of interest
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